KLRC1 and neoplasm: In particular, a humanized anti-NKG2A Ab, Monalizumab (IPH2201), was reported to augment NK cell activity against certain types of tumor cell (B-cell lymphoma, solid tumors, and T-cell lymphoma) and rescue the effector and activation functions CD8+ T and NK cells, especially in combination with PD-L1 blockade (118).